Patents by Inventor Said M. Sebti

Said M. Sebti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
    Patent number: 9486492
    Abstract: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 8, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Compositions including triciribine and one or more platinum compounds and methods of use thereof
    Patent number: 9486470
    Abstract: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 8, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Substrate-mimetic Akt inhibitor
    Patent number: 9453049
    Abstract: Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 27, 2016
    Assignees: University of South Florida, Yale University
    Inventors: Said M. Sebti, Jin Q. Cheng, Andrew D. Hamilton, Katherine Kayser-Bricker
  • Inhibitors of rho associated protein kinases (ROCK) and methods of use
    Patent number: 9409868
    Abstract: Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: August 9, 2016
    Assignee: H. Lee Moffin Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schonbrunn, Rongshi Li, Said M. Sebti
  • Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
    Publication number: 20160206644
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 21, 2016
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Inhibitors of Akt/PKB with anti-tumor activity
    Patent number: 9359347
    Abstract: The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 7, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Mei Sun, Said M. Sebti
  • COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF
    Publication number: 20160136273
    Abstract: This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Application
    Filed: October 13, 2015
    Publication date: May 19, 2016
    Inventors: Jin Q. CHENG, Said M. Sebti
  • COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF
    Publication number: 20160136228
    Abstract: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Application
    Filed: October 19, 2015
    Publication date: May 19, 2016
    Inventors: Jin Q. CHENG, Said M. Sebti
  • PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS
    Publication number: 20160136158
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Application
    Filed: November 20, 2015
    Publication date: May 19, 2016
    Inventors: SAID M. SEBTI, NICHOLAS J. LAWRENCE, JAMES TURKSON
  • Marinopyrrole derivatives as anticancer agents
    Patent number: 9340501
    Abstract: Marinopyrrole derivatives and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing cancer.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: May 17, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Rongshi Li, Said M. Sebti, Yan Liu
  • Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
    Patent number: 9265783
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 23, 2016
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Aurora kinase inhibitors and methods of making and using thereof
    Patent number: 9249124
    Abstract: Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: February 2, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Said M. Sebti, Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Matthew P. Martin
  • COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160000818
    Abstract: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Application
    Filed: August 21, 2015
    Publication date: January 7, 2016
    Inventors: Jin Q. CHENG, Said M. Sebti
  • Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
    Patent number: 9221808
    Abstract: Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: December 29, 2015
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nicholas J. Lawrence, Roberta Pireddu, Said M. Sebti
  • Compositions including triciribine and one or more platinum compounds and methods of use thereof
    Patent number: 9211299
    Abstract: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: December 15, 2015
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
    Patent number: 9192645
    Abstract: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: November 24, 2015
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Compositions including triciribine and trastuzumab and methods of use thereof
    Patent number: 9186403
    Abstract: This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: November 17, 2015
    Assignee: University of South Florida
    Inventors: Jin Q. Cheng, Said M. Sebti
  • EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS
    Publication number: 20150320784
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 12, 2015
    Inventors: Jin Q. CHENG, Said M. Sebti
  • Indoline scaffold SHP-2 inhibitors and cancer treatment method
    Patent number: 9174969
    Abstract: The subject invention concerns methods and compounds for inhibiting Shp2.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: November 3, 2015
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jie Wu, Nicholas J. Lawrence, Said M. Sebti
  • COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF
    Publication number: 20150297621
    Abstract: This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: JIN Q. CHENG, Said M. Sebti